课题基金 / 基金详情

Phage-mediated bioluminescent detection of Yersinia pestis.

Phage-mediated bioluminescent detection of Yersinia pestis.
噬菌体介导的鼠疫耶尔森菌生物发光检测。
批准号:
7664751
负责人:
DAVID A SCHOFIELD
金额:
$11.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-03-12 至 2009-08-31

项目摘要

项目成果

DAVID A SCHOFIELD的其他基金

相关文献

中文摘要
翻译
描述(申请人提供):鼠疫耶尔森氏菌被疾病控制中心(CDC)和NIAID指定为A类优先细菌病原体。鼠疫杆菌是鼠疫(黑死病)的病原体,黑死病是一种传染性疾病,在整个历史过程中造成了数百万人的死亡。虽然这种疾病的自然发生现在相对罕见,但恐怖组织使用鼠疫杆菌作为生物武器的可能性是真实存在的。由于这种疾病固有的传染性、快速的临床病程和高死亡率,迅速发现暴发是至关重要的。因此,提供快速检测和诊断的方法对于确保立即实施公共卫生措施和启动危机管理至关重要。该应用程序的长期目标和商业应用是开发一种鼠疫诊断检测试剂盒。这项第一阶段研究的目标是产生一种能特异性检测鼠疫杆菌的LuxAB(‘light’)标记噬菌体。目前,疾控中心和世界卫生组织(WHO)将鼠疫耶尔森氏菌特异性噬菌体用作确认鼠疫杆菌鉴定的诊断标准;然而,噬菌体裂解试验是以实验室为基础的,需要18-24小时才能完成。相比之下,本申请中描述的技术将不需要样品处理、实验室环境或长时间的孵化期。特定目的1将通过将细菌LuxAB基因整合到鼠疫诊断噬菌体基因组内的非编码区来产生鼠疫报告噬菌体。将根据受感染的培养物发出生物发光的能力来鉴定和分离标记为LuxAB的重组噬菌体。具体目标2将进行可行性研究,以证明LuxAB-噬菌体可以有效地用作鼠疫杆菌检测系统。将使用减毒的鼠疫杆菌菌株(豁免选择剂,BSL2病原体)。将确定检测的灵敏度极限、信号响应时间和剂量-响应特性。总而言之,这项申请将为一种新型的“发光”报告噬菌体的主要研究提供证据,该噬菌体可以快速和特异地检测鼠疫杆菌。我们的初步结果证明了一种基于类似方法检测非包膜炭疽杆菌菌株的可行性。由于NIAID应用研究的未来方向是“鼓励A类病原体的多重诊断技术的发展”(2007年NIAID生物防御研究战略计划),Guild Associates的长期目标之一是开发一种可用于不同A类细菌病原体的诊断鉴定的报告噬菌体鸡尾酒,如炭疽杆菌和鼠疫杆菌。公共卫生相关性:这一应用具有重要意义,因为它将为快速鼠疫诊断检测试剂盒产生原理结果的证据。为了迅速实施挽救生命和防止疾病传播的公共卫生措施,一个快速诊断检测试剂盒是必不可少的。
英文摘要
DESCRIPTION (provided by applicant): Yersinia pestis is designated by the Centers for Disease Control (CDC) and NIAID as a Category A priority bacterial pathogen. Y. pestis is the etiological agent of the plague (Black Death), a transmissible disease that has been responsible for millions of deaths throughout the course of history. Although the natural occurrence of this disease is now relatively rare, the possibility of terrorist groups using Y. pestis as a bioweapon is real. Because of the disease's inherent communicability, rapid clinical course, and high mortality, it is critical that an outbreak be detected quickly. Therefore methodologies that provide rapid detection and diagnosis are essential to ensure immediate implementation of public health measures and activation of crisis management. The long-term goal and commercial application of this application is to develop a plague diagnostic detection kit. The objective of this Phase I research is to generate a luxAB ('light')-tagged phage that can specifically detect Y. pestis. Y. pestis specific phages are currently used by the CDC and the World Health Organization (WHO) as a diagnostic standard for the confirmed identification of Y. pestis; however, the phage lysis assays are laboratory based and require 18-24 h to complete. In contrast, the technology described in this application will not require sample processing, a laboratory environment, or extensive incubation periods. Specific Aim 1 will generate a Y. pestis reporter phage by integrating the bacterial luxAB genes into a non-coding region within the genome of the plague diagnostic phage. Recombinant luxAB-tagged phage will be identified and isolated based on the ability of infected cultures to emit bioluminescence. Specific Aim 2 will perform feasibility studies to demonstrate that the luxAB-phage can effectively be used as a Y. pestis detection system. An attenuated Y. pestis strain (exempt select agent, BSL2 pathogen) will be used. The sensitivity limits of detection, the signal response time, and the dose-response characteristics will be determined. Collectively, this application will generate the proof of principal studies for a novel 'light producing' reporter phage that rapidly and specifically detects Y. pestis. Our preliminary results have demonstrated the feasibility of a similar based approach for the detection of non-encapsulated Bacillus anthracis strains. Since a future direction of NIAID applied research is to "encourage development of multiplex diagnostics" for Category A pathogens (2007 NIAID Strategic Plan for Biodefense Research), one of the long-term goals of Guild Associates is to develop a reporter phage cocktail that can be used for the diagnostic identification of different Category A bacterial pathogens, such as B. anthracis and Y. pestis. PUBLIC HEALTH RELEVANCE: This application is significant because it will generate the proof of principle results for a rapid plague diagnostic test kit. A rapid diagnostic test kit is essential in order to quickly implement public health measures which will save lives and prevent the spread of the disease.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Rapid detection and simultaneous antibiotic susceptibility analysis of Yersinia pestis directly from clinical specimens by use of reporter phage.
使用报告噬菌体直接从临床标本中快速检测鼠疫耶尔森氏菌并同时进行抗生素敏感性分析。
DOI: 10.1128/jcm.00316-14
发表时间: 2014
期刊: Journal of clinical microbiology
影响因子: 9.4
作者: [Vandamm,JP, Rajanna,C, Sharp,NJ, Molineux,IJ, Schofield,DA]
通讯作者: Schofield,DA
DOI: 10.1002/jez.1402560444
发表时间: 1990
期刊: The Journal of experimental zoology. Supplement : published under auspices of the American Society of Zoologists and the Division of Comparative Physiology and Biochemistry
影响因子: --
作者: [Concannon,PW, Baldwin,B, Roberts,P, Tennant,B]
通讯作者: Tennant,B
'Bioluminescent' reporter phage for the detection of Category A bacterial pathogens.
用于检测 A 类细菌病原体的“生物发光”报告噬菌体。
DOI: 10.3791/2740
发表时间: 2011
期刊: Journal of visualized experiments : JoVE
影响因子: --
作者: [Schofield,DavidA, Molineux,IanJ, Westwater,Caroline]
通讯作者: Westwater,Caroline
Phage-accelerated test system for ID/AST of urinary tract infections
  • 批准号:
    9407512
  • 项目类别:
  • 资助金额:
    $29.11万
  • 财政年份:
    2017
  • 负责人:
    DAVID A SCHOFIELD
  • 依托单位:
Bioluminescent reporter phage for the diagnostic detection of shigellosis
  • 批准号:
    8839507
  • 项目类别:
  • 资助金额:
    $42.96万
  • 财政年份:
    2014
  • 负责人:
    DAVID A SCHOFIELD
  • 依托单位:
Detection of Biodefense Pathogens Using Phage Diagnostics
  • 批准号:
    8694755
  • 项目类别:
  • 资助金额:
    $47.28万
  • 财政年份:
    2014
  • 负责人:
    DAVID A SCHOFIELD
  • 依托单位:
Detection of Biodefense Pathogens Using Phage Diagnostics
  • 批准号:
    8819100
  • 项目类别:
  • 资助金额:
    $74.54万
  • 财政年份:
    2014
  • 负责人:
    DAVID A SCHOFIELD
  • 依托单位: